Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine.
Yang M, Rendas-Baum R, Varon SF, Kosinski M. · 2011
Read Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. by Yang M, Rendas-Baum R, Varon SF, Kosinski M. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3057423.txt.
Introduction
Yang, Rendas-Baum, Varon, and Kosinski checked in 2011 whether a short questionnaire on headache impact works equally well for occasional and for chronic migraine. The six question survey, called HIT-6 in short, asks how headaches limit work, home life, and mood. The team drew on two large survey datasets covering more than two thousand people with migraine or other headaches.
Scores were consistent when the survey was repeated, and they lined up with disability scores, pain severity, and monthly headache days as expected. People with chronic migraine, defined by very frequent headache days, scored highest, those with episodic migraine scored close behind, and those with non migraine headaches scored much lower. The gaps between groups were large and clear. The authors conclude the short survey is a reliable, valid way to compare headache burden across the migraine spectrum in clinics and research.
Catalog record
| CREATOR | Yang M, Rendas-Baum R, Varon SF, Kosinski M. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine By Min Yang, Regina Rendas-Baum, Sepideh F Varon, Mark Kosinski Published in: Cephalalgia DOI: 10.1177/0333102410379890 ABSTRACT Abstract Objective: The purpose of this study was to assess psychometric properties of the six-item Headache Impact Text (HIT-6™) across episodic and chronic migraine. Methods: Using a migraine screener and number of headache days per month (HDPM), participants from the National Survey of Headache Impact (NSHI) study and the HIT-6 validation study (HIT6-V) were selected for this study. Eligible participants were categorized into three groups: chronic migraine (CM: ≥ 15 HDPM); episodic migraine (EM: < 15 HDPM); non-migraine headaches. Reliability and validity of the HIT-6 were evaluated. Results: A total of 2,049 survey participants met the inclusion/exclusion criteria for this study. Participants were identified as 6.4% CM; 42.1% EM; 51.5% non-migraine, with respective mean HIT-6 scores: 62.5 ± 7.8; 60.2 ± 6.8; and 49.1 ± 8.7. High reliability was demonstrated with internal consistency (time1/time2) of 0.83/0.87 in NSHI, and 0.82/0.92 in HIT6-V. Intra-class correlation for test-retest reliability was very good at 0.77. HIT-6 scores correlated significantly (p < .0001) with total Migraine Disability Assessment Scale scores (r = 0.56), headache pain severity (r = 0.46), and HDPM (r = 0.29). Discriminant validity analysis showed significantly different HIT-6 scores (F = 488.02, p < .0001) across the groups. Conclusion: Results from these analyses confirm that the HIT-6 is a reliable and valid tool for discriminating headache impact across episodic and chronic migraine. Keywords: HIT-6, migraine, chronic migraine, episodic migraine, headache INTRODUCTION Migraine is a prevalent and disabling condition that affects approximately 12% of the population in the Western countries (1,2). The detrimental effects of migraine are well documented. Migraine interferes with an individual’s physical functioning, work productivity, leisure activities, lifestyle and psychological well-being (3–7). Furthermore, research has shown that the level of disability differs according to frequency of headache events. According to Bigal and Lipton (8–10), many patients with migraine can experience the disease progression clinically, physiologically, and anatomically. The typical clinical progression of migraine is defined by the frequency of headache days. Individuals with episodic migraine (EM), defined as having <15 headache days per month (HDPM), may progress to chronic migraine (CM), defined as ≥15 HDPM (8–10). While the pathophysiology of the transformation from episodic to chronic migraine is not well understood, CM has been shown to be significantly more debilitating than episodic migraine (3,6,11). Regardless of its disruptive effect, migraine is frequently underdiagnosed and undertreated (2,6,12). A potential reason, as proposed by Bigal et al. (6), is the lack of physician confidence in the diagnosis of chronic headache conditions and their subtypes. The International Classification of Headache Disorders, second edition (ICHD-II) (13), introduced diagnostic criteria for CM, a complication of migraine. Subsequently, the criteria were refined and revised to more accurately reflect the large majority of CM patients seen in clinical practice (14). Outcome measures to capture the impact of the disorder, beyond the frequency of headache episodes or headache days, have been recommended and used by clinical experts (15–18). These measures have most commonly been used in studies of acute and prophylactic treatments for episodic migraine. Few trials have reported evaluation of treatments for CM (14). Clinical evaluation of migraine-related disability or quality of life plays an important role in migraine research and patient management in clinical practice. To our knowledge, none of the measures that evaluate disability or quality of life have been psychometrically validated for differentiating between the persons with EM disorder (<15 HDPM) and CM disorder (≥15 HDPM). The six-item Headache Impact Test (HIT-6) was designed to provide a global measure of adverse headache impact (19,20) and was developed to use in screening and monitoring patients with headaches in both clinical practice and clinical research (20). The HIT-6 items measure the adverse impact of headache on social functioning, role functioning, vitality, cognitive functioning and psychological distress. The HIT-6 also measures the severity of headache pain. The six items were selected from 89 items (54 from an existing adverse headache impact item pool and 35 items recommended by clinicians) (20). The HIT-6 shows good internal consistency and test-retest reliability, construct validity and responsiveness in general headache patients (19–21). Since its initial development and validation, the HIT-6 has been well received and widely utilized in clinical practice, and applied to clinical trials for patient screening and treatment monitoring of headaches, including migraine (22–28). The HIT-6 was developed among headache sufferers with different headache day frequency and severity levels. Given the increasing use of the HIT-6 in clinical management of patients, as well as in clinical research, it is necessary to provide evidence for the reliability and validity of the HIT-6 in migraine patients who suffer varying headache day frequency. The purpose of this study was to evaluate the reliability and validity of the HIT-6 among migraine patients, and its ability in discriminating headache impact and the level of disability between EM and CM disorders. METHODS Data sources Data came from two sources of adult participants with recent headache complaints: (i) the National Survey of Headache Impact (NSHI) study (19) and (ii) the HIT-6 Validation (HIT6-V) study (20). The NSHI study was a 1999 telephone interview survey study using a randomly generated list of household telephone numbers from 48 states of the USA. Eligible participants were: (i) 18 to 65 years of age; (ii) permanent US residents; (iii) those with at least one headache in the four weeks prior to the interview that was not related to a cold, flu, a head injury or a hangover; and (iv) able to converse easily in English. Follow-up interviews after three months were completed for a subgroup of respondents randomly selected from the initial respondents to represent mild, moderate and severe headache sufferers. The severity levels associated with pain from headaches in general were derived based on a numeric rating scale of headache pain from 0 to 10, 0 representing “no pain” and 10 representing “pain as bad as it can be.” Mild headache pain was defined by scores 1–4; moderate by scores 5–7; and severe by scores 8–10. The purpose of the NSHI study was to obtain empirical data for the development of the Headache Impact Test item pool using 54 items from four widely used measures of headache impact, along with 35 new experimental items proposed by clinicians (19,21). The four headache impact measures were administered in the following order: (i) the Migraine Disability Assessment (MIDAS) score; (ii) the Migraine-Specific Quality of Life (MSQ) questionnaire; (iii) the Headache Impact Questionnaire (HIMQ); and (iv) the Headache Disability Inventory (HDI). Details of the NSHI have been described elsewhere (19). Data of the HIT6-V study were collected in 2000 through the America Online (AOL) Opinion Place from AOL subscribers who were (i) 18 to 65 years of age, (ii) with at least one headache in the past four weeks not related to a cold, flu, a head injury or a hangover; and (iii) agreed to be contacted again in two weeks to complete the follow-up survey. At time 1, the HIT-6 was administered first followed by the MIDAS and the QualityMetric's Short-Form (SF)-8 Health Survey (which measures eight health domains). At time 2, this